211 related articles for article (PubMed ID: 37354211)
41. Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma.
Li L; Xiao Z; He P; Zou W; Deng Z; Zhang G; Liu R
BMC Gastroenterol; 2022 Nov; 22(1):454. PubMed ID: 36371178
[TBL] [Abstract][Full Text] [Related]
42. Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma.
Zou J; Zhang K; Zhu J; Tu C; Guo J
J Int Med Res; 2024 Jan; 52(1):3000605231218559. PubMed ID: 38180878
[TBL] [Abstract][Full Text] [Related]
43. High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma.
Zhu Y; Zheng D; Lei L; Cai K; Xie H; Zheng J; Yu C
BMC Cancer; 2022 Oct; 22(1):1042. PubMed ID: 36199068
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive analysis of the prognosis of S100 family members and their relationship with tumor-infiltrating immune cells in human pancreatic adenocarcinoma.
Ren Y; Chen B; Zhang M; Xu F
Medicine (Baltimore); 2023 Feb; 102(8):e32976. PubMed ID: 36827067
[TBL] [Abstract][Full Text] [Related]
45. Transmembrane Protein 170B is a Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic Adenocarcinoma.
Zhang Z; Shang J; Dai Z; Yao Y; Shi Y; Zhong D; Liang Y; Lai C; Yang Q; Feng T; Huang X
Front Genet; 2022; 13():848391. PubMed ID: 35601487
[No Abstract] [Full Text] [Related]
46. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
Tian C; Li X; Ge C
Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
[TBL] [Abstract][Full Text] [Related]
47. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
Wang C; Wang Z; Zhao Y; Jia R
BMC Gastroenterol; 2022 Nov; 22(1):495. PubMed ID: 36451085
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive analyses and experimental verification of NETs and an EMT gene signature for prognostic prediction, immunotherapy, and chemotherapy in pancreatic adenocarcinoma.
Zhang J; Wang C; Yu Y
Environ Toxicol; 2024 Apr; 39(4):2006-2023. PubMed ID: 38088494
[TBL] [Abstract][Full Text] [Related]
49. Role of Up-Regulated Transmembrane Channel-Like Protein 5 in Pancreatic Adenocarcinoma.
Gan XY; Li JD; Chen G; He RQ; Luo JY; Zeng JJ; Yang ZX; Yao YX; Zhu JJ; Li JJ; Wei DM
Dig Dis Sci; 2023 May; 68(5):1894-1912. PubMed ID: 36459296
[TBL] [Abstract][Full Text] [Related]
50. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.
Zhou C; Wang L; Hu W; Tang L; Zhang P; Gao Y; Du J; Li Y; Wang Y
Bioengineered; 2022 May; 13(5):13089-13107. PubMed ID: 35615982
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive Analysis of SMC Gene Family Prognostic Value and Immune Infiltration in Patients With Pancreatic Adenocarcinoma.
Nie H; Wu Y; Ou C; He X
Front Med (Lausanne); 2022; 9():832312. PubMed ID: 35372377
[TBL] [Abstract][Full Text] [Related]
52. Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma.
Wu Z; Huang X; Cai M; Huang P; Guan Z
Aging (Albany NY); 2022 Jan; 14(2):869-891. PubMed ID: 35077391
[TBL] [Abstract][Full Text] [Related]
53. LACTB mRNA expression is increased in pancreatic adenocarcinoma and high expression indicates a poor prognosis.
Xie J; Peng Y; Chen X; Li Q; Jian B; Wen Z; Liu S
PLoS One; 2021; 16(1):e0245908. PubMed ID: 33507917
[TBL] [Abstract][Full Text] [Related]
54. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
55. Gene coexpression network approach to develop an immune prognostic model for pancreatic adenocarcinoma.
Gu X; Zhang Q; Wu X; Fan Y; Qian J
World J Surg Oncol; 2021 Apr; 19(1):112. PubMed ID: 33845841
[TBL] [Abstract][Full Text] [Related]
56. miR‑32‑5p suppresses the proliferation and migration of pancreatic adenocarcinoma cells by targeting TLDC1.
Yuan P; Tang C; Chen B; Lei P; Song J; Xin G; Wang Z; Hui Y; Yao W; Wang G; Zhao G
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34468015
[TBL] [Abstract][Full Text] [Related]
57. BDNF Acts as a Prognostic Factor Associated with Tumor-Infiltrating Th2 Cells in Pancreatic Adenocarcinoma.
Zhu Y; Zhang C; Zhao D; Li W; Zhao Z; Yao S; Zhao D
Dis Markers; 2021; 2021():7842035. PubMed ID: 34777634
[TBL] [Abstract][Full Text] [Related]
58. Cuproptosis-Related Gene
Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
[TBL] [Abstract][Full Text] [Related]
59. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
Front Genet; 2021; 12():752025. PubMed ID: 35046996
[No Abstract] [Full Text] [Related]
60. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
